-+ 0.00%
-+ 0.00%
-+ 0.00%

Structure Therapeutics Launches Phase 1 Trial of Oral Amylin Agonist ACCG-2671 for Obesity

Reuters·12/17/2025 13:30:32

Please log in to view news